-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, April 16th, April 15th, the official website of NMPA showed that Chengdu Yuandong Biotechnology Co.
, Ltd.
was approved to produce propofol fumarate tenofovir tablets and dabigatran etexilate capsules with imitations of the 4 types of production.
Same comment.
Dabigatran etexilate capsules and propofol tenofovir fumarate tablets are anticoagulant drugs and hepatitis B drugs, respectively.
In 2020, global sales will be US$1.
7 billion and US$659 million, respectively.
Dabigatran etexilate capsules were included in the fifth batch of collective procurement report.
, Ltd.
was approved to produce propofol fumarate tenofovir tablets and dabigatran etexilate capsules with imitations of the 4 types of production.
Same comment.
Dabigatran etexilate capsules and propofol tenofovir fumarate tablets are anticoagulant drugs and hepatitis B drugs, respectively.
In 2020, global sales will be US$1.
7 billion and US$659 million, respectively.
Dabigatran etexilate capsules were included in the fifth batch of collective procurement report.
Yuandong Bio's Propofol Fumarate Tenofovir Tablets and Dabigatran Etexilate Capsules were approved for production on the same day.
The approval numbers are H20213274, H20213281 and H20213282 respectively.
The approval numbers are H20213274, H20213281 and H20213282 respectively.
Profol tenofovir (Vemlidy) is a powerful antiviral drug developed by Gilead for the treatment of chronic hepatitis B in adults and adolescents.
It is the first-line drug for the treatment of hepatitis B in the world.
Its global sales in 2020 will be US$655 million.
Prior to this, Tenofovir fumarate tablets from Better Pharmaceuticals, Jiangxi Qingfeng Pharmaceuticals, Qilu Pharmaceuticals and Kelun Pharmaceuticals have been approved for production.
It is the first-line drug for the treatment of hepatitis B in the world.
Its global sales in 2020 will be US$655 million.
Prior to this, Tenofovir fumarate tablets from Better Pharmaceuticals, Jiangxi Qingfeng Pharmaceuticals, Qilu Pharmaceuticals and Kelun Pharmaceuticals have been approved for production.
Dabigatran etexilate belongs to the β-alanine thrombin inhibitor, which is converted into dabigatran with direct anticoagulant activity in the body after oral absorption through the gastrointestinal tract.
It is used to prevent stroke in patients with non-valvular atrial fibrillation And systemic embolism.
The product was developed by Boehringer Ingelheim and has global sales of 1.
492 billion euros (approximately 1.
7 billion US dollars) in 2020.
It is used to prevent stroke in patients with non-valvular atrial fibrillation And systemic embolism.
The product was developed by Boehringer Ingelheim and has global sales of 1.
492 billion euros (approximately 1.
7 billion US dollars) in 2020.
According to data from Meinenet, in 2019, the total sales of dabigatran etexilate in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and the terminal dabigatran etexilate of Chinese urban physical pharmacies exceeded 800 million yuan.
In recent years, the market size of dabigatran etexilate has maintained double-digit growth.
In 2019, the growth rate of terminal sales in physical pharmacies in Chinese cities exceeded 40%.
In recent years, the market size of dabigatran etexilate has maintained double-digit growth.
In 2019, the growth rate of terminal sales in physical pharmacies in Chinese cities exceeded 40%.
Sales of dabigatran etexilate at physical pharmacies in cities in China
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
On April 15th, the fifth batch of collectively collected varieties was out of the catalog, and the oral dosage forms of dabigatran etexilate (75mg, 110mg, 150mg) were listed.
Yuandong Biological will compete with Zhengda Tianqing Pharmaceutical Group, Jiangsu Haosen Pharmaceutical and Chengdu Better Pharmaceuticals for the share of collective procurement of dabigatran etexilate capsules.
Yuandong Biological will compete with Zhengda Tianqing Pharmaceutical Group, Jiangsu Haosen Pharmaceutical and Chengdu Better Pharmaceuticals for the share of collective procurement of dabigatran etexilate capsules.
Yuandong Biological passed/deemed passed consistency evaluation varieties
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
So far, Yuandong Bio has 14 varieties (25 product specifications) passed/deemed to pass the consistency evaluation, including bisoprolol fumarate tablets, ibuprofen injection, memantine hydrochloride sustained-release capsules and iban Four varieties including phosphonate sodium injection were the first to be reviewed.
Medical Network News, April 16th, April 15th, the official website of NMPA showed that Chengdu Yuandong Biotechnology Co.
, Ltd.
was approved to produce propofol fumarate tenofovir tablets and dabigatran etexilate capsules with imitations of the 4 types of production.
Same comment.
Dabigatran etexilate capsules and propofol tenofovir fumarate tablets are anticoagulant drugs and hepatitis B drugs, respectively.
In 2020, global sales will be US$1.
7 billion and US$659 million, respectively.
Dabigatran etexilate capsules were included in the fifth batch of collective procurement report.
, Ltd.
was approved to produce propofol fumarate tenofovir tablets and dabigatran etexilate capsules with imitations of the 4 types of production.
Same comment.
Dabigatran etexilate capsules and propofol tenofovir fumarate tablets are anticoagulant drugs and hepatitis B drugs, respectively.
In 2020, global sales will be US$1.
7 billion and US$659 million, respectively.
Dabigatran etexilate capsules were included in the fifth batch of collective procurement report.
Yuandong Bio's Propofol Fumarate Tenofovir Tablets and Dabigatran Etexilate Capsules were approved for production on the same day.
The approval numbers are H20213274, H20213281 and H20213282 respectively.
The approval numbers are H20213274, H20213281 and H20213282 respectively.
Profol tenofovir (Vemlidy) is a powerful antiviral drug developed by Gilead for the treatment of chronic hepatitis B in adults and adolescents.
It is the first-line drug for the treatment of hepatitis B in the world.
Its global sales in 2020 will be US$655 million.
Prior to this, Tenofovir fumarate tablets from Better Pharmaceuticals, Jiangxi Qingfeng Pharmaceuticals, Qilu Pharmaceuticals and Kelun Pharmaceuticals have been approved for production.
It is the first-line drug for the treatment of hepatitis B in the world.
Its global sales in 2020 will be US$655 million.
Prior to this, Tenofovir fumarate tablets from Better Pharmaceuticals, Jiangxi Qingfeng Pharmaceuticals, Qilu Pharmaceuticals and Kelun Pharmaceuticals have been approved for production.
Dabigatran etexilate belongs to the β-alanine thrombin inhibitor, which is converted into dabigatran with direct anticoagulant activity in the body after oral absorption through the gastrointestinal tract.
It is used to prevent stroke in patients with non-valvular atrial fibrillation And systemic embolism.
The product was developed by Boehringer Ingelheim and has global sales of 1.
492 billion euros (approximately 1.
7 billion US dollars) in 2020.
It is used to prevent stroke in patients with non-valvular atrial fibrillation And systemic embolism.
The product was developed by Boehringer Ingelheim and has global sales of 1.
492 billion euros (approximately 1.
7 billion US dollars) in 2020.
According to data from Meinenet, in 2019, the total sales of dabigatran etexilate in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and the terminal dabigatran etexilate of Chinese urban physical pharmacies exceeded 800 million yuan.
In recent years, the market size of dabigatran etexilate has maintained double-digit growth.
In 2019, the growth rate of terminal sales in physical pharmacies in Chinese cities exceeded 40%.
In recent years, the market size of dabigatran etexilate has maintained double-digit growth.
In 2019, the growth rate of terminal sales in physical pharmacies in Chinese cities exceeded 40%.
Sales of dabigatran etexilate at physical pharmacies in cities in China
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
On April 15th, the fifth batch of collectively collected varieties was out of the catalog, and the oral dosage forms of dabigatran etexilate (75mg, 110mg, 150mg) were listed.
Yuandong Biological will compete with Zhengda Tianqing Pharmaceutical Group, Jiangsu Haosen Pharmaceutical and Chengdu Better Pharmaceuticals for the share of collective procurement of dabigatran etexilate capsules.
Yuandong Biological will compete with Zhengda Tianqing Pharmaceutical Group, Jiangsu Haosen Pharmaceutical and Chengdu Better Pharmaceuticals for the share of collective procurement of dabigatran etexilate capsules.
Yuandong Biological passed/deemed passed consistency evaluation varieties
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
So far, Yuandong Bio has 14 varieties (25 product specifications) passed/deemed to pass the consistency evaluation, including bisoprolol fumarate tablets, ibuprofen injection, memantine hydrochloride sustained-release capsules and iban Four varieties including phosphonate sodium injection were the first to be reviewed.
Medical Network News, April 16th, April 15th, the official website of NMPA showed that Chengdu Yuandong Biotechnology Co.
, Ltd.
was approved to produce propofol fumarate tenofovir tablets and dabigatran etexilate capsules with imitations of the 4 types of production.
Same comment.
Dabigatran etexilate capsules and propofol tenofovir fumarate tablets are anticoagulant drugs and hepatitis B drugs, respectively.
In 2020, global sales will be US$1.
7 billion and US$659 million, respectively.
Dabigatran etexilate capsules were included in the fifth batch of collective procurement report.
, Ltd.
was approved to produce propofol fumarate tenofovir tablets and dabigatran etexilate capsules with imitations of the 4 types of production.
Same comment.
Dabigatran etexilate capsules and propofol tenofovir fumarate tablets are anticoagulant drugs and hepatitis B drugs, respectively.
In 2020, global sales will be US$1.
7 billion and US$659 million, respectively.
Dabigatran etexilate capsules were included in the fifth batch of collective procurement report.
Yuandong Bio's Propofol Fumarate Tenofovir Tablets and Dabigatran Etexilate Capsules were approved for production on the same day.
The approval numbers are H20213274, H20213281 and H20213282 respectively.
The approval numbers are H20213274, H20213281 and H20213282 respectively.
Profol tenofovir (Vemlidy) is a powerful antiviral drug developed by Gilead for the treatment of chronic hepatitis B in adults and adolescents.
It is the first-line drug for the treatment of hepatitis B in the world.
Its global sales in 2020 will be US$655 million.
Prior to this, Tenofovir fumarate tablets from Better Pharmaceuticals, Jiangxi Qingfeng Pharmaceuticals, Qilu Pharmaceuticals and Kelun Pharmaceuticals have been approved for production.
It is the first-line drug for the treatment of hepatitis B in the world.
Its global sales in 2020 will be US$655 million.
Prior to this, Tenofovir fumarate tablets from Better Pharmaceuticals, Jiangxi Qingfeng Pharmaceuticals, Qilu Pharmaceuticals and Kelun Pharmaceuticals have been approved for production.
Dabigatran etexilate belongs to the β-alanine thrombin inhibitor, which is converted into dabigatran with direct anticoagulant activity in the body after oral absorption through the gastrointestinal tract.
It is used to prevent stroke in patients with non-valvular atrial fibrillation And systemic embolism.
The product was developed by Boehringer Ingelheim and has global sales of 1.
492 billion euros (approximately 1.
7 billion US dollars) in 2020.
It is used to prevent stroke in patients with non-valvular atrial fibrillation And systemic embolism.
The product was developed by Boehringer Ingelheim and has global sales of 1.
492 billion euros (approximately 1.
7 billion US dollars) in 2020.
According to data from Meinenet, in 2019, the total sales of dabigatran etexilate in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and the terminal dabigatran etexilate of Chinese urban physical pharmacies exceeded 800 million yuan.
In recent years, the market size of dabigatran etexilate has maintained double-digit growth.
In 2019, the growth rate of terminal sales in physical pharmacies in Chinese cities exceeded 40%.
Hospital hospital hospital pharmacy pharmacy pharmacyIn recent years, the market size of dabigatran etexilate has maintained double-digit growth.
In 2019, the growth rate of terminal sales in physical pharmacies in Chinese cities exceeded 40%.
Sales of dabigatran etexilate at physical pharmacies in cities in China
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
On April 15th, the fifth batch of collectively collected varieties was out of the catalog, and the oral dosage forms of dabigatran etexilate (75mg, 110mg, 150mg) were listed.
Yuandong Biological will compete with Zhengda Tianqing Pharmaceutical Group, Jiangsu Haosen Pharmaceutical and Chengdu Better Pharmaceuticals for the share of collective procurement of dabigatran etexilate capsules.
Yuandong Biological will compete with Zhengda Tianqing Pharmaceutical Group, Jiangsu Haosen Pharmaceutical and Chengdu Better Pharmaceuticals for the share of collective procurement of dabigatran etexilate capsules.
Yuandong Biological passed/deemed passed consistency evaluation varieties
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
So far, Yuandong Bio has 14 varieties (25 product specifications) passed/deemed to pass the consistency evaluation, including bisoprolol fumarate tablets, ibuprofen injection, memantine hydrochloride sustained-release capsules and iban Four varieties including phosphonate sodium injection were the first to be reviewed.
